Journal article
The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial
Abstract
AIMS: The aim of this study was to evaluate the effects of apixaban, a novel oral factor Xa inhibitor, on the need for cardiovascular hospitalization.
METHODS AND RESULTS: Our analysis is based on data from AVERROES, a randomized double-blind trial testing the efficacy and safety of apixaban against aspirin for the prevention of thrombo-embolism in 5599 atrial fibrillation (AF) patients unsuitable for vitamin K antagonist therapy. …
Authors
Hohnloser SH; Shestakovska O; Eikelboom J; Franzosi MG; San Tan R; Zhu J; Yusuf S; Connolly SJ
Journal
European Heart Journal, Vol. 34, No. 35, pp. 2752–2759
Publisher
Oxford University Press (OUP)
Publication Date
September 1, 2013
DOI
10.1093/eurheartj/eht292
ISSN
0195-668X